Midostaurin and the other FLT3 inhibitors, as expected, most potently suppressed the growth of FLT3‐ITD–positive MOLM14 cells; however, the inhibitors effectively killed wt FLT3‐expressing AML lines at submicromolar concentrations (Figure 1A‐E). The gene discussed is FLT3; the disease is acute myeloid leukemia.